Multiplex Analysis of the Immune Environment Before and after Neoadjuvant Durvalumab As a Prognostic Factor in Resectable Non-Small Cell Lung Cancer (NSCLC) in the IFCT-1601 IONESCO Phase 2 Trial.
Journal of Clinical Oncology(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined